A phase II trial of edatrexate in previously treated squamous cell cervical cancer: A Gynecologic Oncology Group Study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 1, 1997, Pages 78-80

  Broun, E Randolph ^a,i   Iseminger, Karen A ^b   Rose, Peter G ^c,h   Lentz, Samuel L ^d   Malfetano, John H ^e   Lincoln, Sarah ^f   Mannel, Robert ^g  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e ALBANY MEDICAL CENTER   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁱ Div Bone Marrow Transplant H   (United States)

Author keywords

Cervical cancer; Edatrexate; Fanconi's syndrome

Indexed keywords

CISPLATIN; EDATREXATE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FANCONI RENOTUBULAR SYNDROME; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SEPSIS; SQUAMOUS CELL CARCINOMA; STOMATITIS; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; AMINOPTERIN; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FANCONI SYNDROME; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; UTERINE CERVICAL NEOPLASMS;

EID: 0031030816     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199702000-00017     Document Type: Article

References (18)

1. Chello PL, Sirotnak FM, Dorick DM, et al. Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells. Cancer Res 1977;37:4297-303.
2. Sirotnak FM. Correlates of folate analog transport, pharmacokinetics and selective antitumor action. Pharmacol Ther 1980;8:71-103.
3. Sirotnak FM, Chello PL, Piper JR, et al. Growth inhibitory transport and biochemical properties of the glutamyl and aspartyl peptides of methotrexate in L1210 leukemia cells in vitro. Biochem Pharmacol 1978;27:1821-5.
4. Sirotnak FM, Chello PL, Brockman RW. Potential for exploitation of transport systems in anticancer drug design. In: Busch H, DeVita VT, eds. Methods in cancer research. New York: Academic Press, 1979:381-447.
5. Moccio DM, Sirotnak FM, Samuels LL, et al. Similar specificity of membrane transport for folate analogues and their metabolites by murine and human tumor cells: A clinically directed laboratory study. Cancer Res 1984;44:352-7.
6. Kris MG, Kinahan JJ, Gralla RJ, et al. Phase I and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. Cancer Res 1988;48: 5573-9.
7. Thigpen T, Shingleton H, Homesley H, et al. Cis-dichloro-diammineplatinum (II) in the treatment of gynecologic malignancies: Phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 1979;63:1549-55.
8. Bonomi P, Blessing JA, Stehman F, et al. Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix (A Gynecologic Oncology Group study). J Clin Oncol 1985;3:1079-85.
9. Sutton GP, Blessing JA, McGuire W, Patton T, Look KY. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: A gynecologic oncology group study. Am J Obstet Gynecol 1993;168:805-7.
10. Stehman FB, Blessing JA, McGehee R, Barrett RJ. A phase II evaluation of dibromodulcitol in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 1989;7:1892-5.
11. Pritchard JB, Miller DS. Proximal tubular transport of organic anions and cations, In: Seldin DW, Giesbisch G, eds. The kidney: physiology and pathophysiology. New York: Raven Press. 1992:2947-69.
12. Maldonado JE, Velosa JA, Kyle RA, Wagoner RD, Holley KE, Salassa RM. Fanconi syndrome in adults: A manifestation of a latent form of myeloma. Am J Med 1975;58:354-64.
13. Gross JJM. Fanconi syndrome (adult type) developing secondary to the ingestion of outdated tetracycline. Ann Intern Med 1963;58:423-8.
14. Melnick JZ, Baum M, Thompson JR. Aminoglycoside-induced Fanconi's syndrome. Am J Kidney Dis 1994;23:118-22.
15. Rossi R, Ehrich JH. Partial and complete de Toni-Debre-Fanconi syndrome after ifosfamide chemotherapy of childhood malignancy. Eur J Clin Pharmacol 1993;44(suppl 1):S43-5.
16. VanGool S, Brock P, Wijndaele G, et al. Reversible hypo-phosphatemic following ifosfamide treatment. Med Pediatr Oncol 1992;20:254-7.
17. Rossi R, Danzebrink S, Hillebrand D, Linnenburger K, Ullrich K, Jurgens H. Ifosfamide induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol 1994;22:27-32.
18. Beckwith C, Flaharty KK, Cheung AK, Beatty PG. Fanconi's syndrome due to ifosfamide. Bone Marrow Transplant 1993;11:71-3.